Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 plus Lenvatinib in HCC
NCT06034977Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Dec 2023; status: recruiting.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06034977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034977.